Modified Vaccinia Vectors Enhance Immunogenicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective immunological compositions and methods for immunizing animals and humans using recombinant vectors, as existing vectors such as replication-incompetent vaccinia vectors are insufficient as immunomodulators.
Innovation Solution
The development of modified recombinant viral vectors by deleting or inserting nucleic acids encoding specific polypeptides, such as B8R and B19R, to enhance immunogenicity and alter the host range and replicative capacity of the vectors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If replication-incompetent vaccinia vectors are used, then safety is improved, but immunogenicity is insufficient
Solution Approach 1:
The patent modifies the replication-incompetent vaccinia vector by introducing specific genetic modifications that change its biological parameters. These modifications enable the vector to replicate to some extent while maintaining safety, thereby enhancing its immunogenicity and ability to induce strong immune responses against heterologous antigens.
Solution Approach 2:
The patent creates a composite viral vector system that combines the safety features of replication-incompetent vectors with the enhanced immunogenicity provided by specific genetic modifications. This composite approach integrates multiple functional elements into a single vector system that achieves both safety and high immunogenicity.
2Quantity of substance
If vectors are modified to enhance immunogenicity, then immunogenicity is improved, but vector complexity increases
Solution Approach 1:
The patent employs segmentation by dividing the vector modification process into distinct steps: identifying specific genetic regions to modify, introducing particular genes or genetic elements, and verifying the desired immunogenicity. This segmented approach makes the complex modification process more manageable and reproducible.
Solution Approach 2:
The patent uses intermediary vectors or plasmids as mediators to facilitate the genetic modifications. These intermediary elements serve as temporary carriers that enable the introduction of specific genes into the vaccinia vector without directly manipulating the complex viral genome, thereby simplifying the overall process.
Data Source
AI summary
The disclosure relates to recombinant vectors and methods for using the same. In certain embodiments, the recombinant vectors are immunogenic.